Brief: Cingulate Inc - On April 24, 2023, Co Entered Into A Purchase Agreement And A Registration Rights Agreement With Lincoln Park Capital Fund, Llc
Brief: Cingulate Completes First Cohort Of Phase 3 Adult Onset And Duration Trial Of Ctx-1301 (Dexmethylphenidate) For Adhd
Brief: Cingulate -Confirms It Does Not Hold Any Cash Deposits, Securities, Maintain Any Accounts At Or Have Any Banking Relationship With, Silicon Valley Bank
Brief: Cingulate And Indegene Announce Joint Commercialization Agreement For Lead ADHD Candidate CTx-1301
Brief: Cingulate Inc. Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Clinical And Business Update
Brief: Cingulate Announces Positive Top-Line Results From Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd
Brief: Cingulate Initiates Phase 3 Study Of Lead Asset Ctx-1301, Designed As A True Entire Active-Day Treatment For ADHD
Brief: Cingulate Files For Mixed Shelf Of Up To $100 Mln
U.S. RESEARCH ROUNDUP- Boeing, Intel, Silvergate Capital
Brief: Cingulate Inc Reports Q3 Loss Of $0.36 Per Share
Brief: Cingulate Announces Agreement With Societal Cdmo
Brief: Cingulate Presents Data For Triple-Release Buspirone Product Candidate Ctx-2103
Brief: Cingulate reports Q2 results
Brief: Cingulate Completes CTx-2103 Human Formulation Study For Anxiety Disorders Treatment
Brief: Cingulate Announces Complete Enrollment In Human Formulation Study Of CTx-2103 For Treatment Of Anxiety Disorders
Brief: Cingulate Reports Q1 2022 Results
Brief: Cingulate Inc Reports Fourth Quarter And Full Year 2021 Results And Provides Clinical And Business Update
Brief: Cingulate Provides 2022 Clinical Plan For CTX-1301
Brief: Cingulate Appoints Curt Medeiros And Gregg Givens To Board Of Directors